Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 240

1.

Novel preventive and therapeutic strategies against HIV infection.

Jaworski JP, Frola C, Cahn P.

Medicina (B Aires). 2019;79(Spec 6/1):534-539.

2.

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.

Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man CY, Urbaityte R, Brandon DJ, Underwood M, Tenorio AR, Pappa KA, Wynne B, Gartland M, Aboud M, van Wyk J, Smith KY.

J Acquir Immune Defic Syndr. 2019 Dec 10. doi: 10.1097/QAI.0000000000002275. [Epub ahead of print]

PMID:
31834000
3.

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.

Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Rodgers A, Lupinacci L, Kumar S, Sklar P, Hanna GJ, Hwang C, Martin EA; DRIVE-FORWARD trial group.

Lancet HIV. 2020 Jan;7(1):e16-e26. doi: 10.1016/S2352-3018(19)30336-4. Epub 2019 Nov 15.

PMID:
31740348
4.

Women of Reproductive Age Living with HIV in Argentina: Unique Challenges for Reengagement in Care.

Cecchini D, Alcaide ML, Rodriguez VJ, Mandell LN, Abbamonte JM, Cassetti I, Cahn P, Sued O, Weiss SM, Jones DL.

J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958219883250. doi: 10.1177/2325958219883250.

5.

Liver cirrhosis in HIV/HCV-coinfected individuals is related to NK cell dysfunction and exhaustion, but not to an impaired NK cell modulation by CD4+ T-cells.

Polo ML, Ghiglione YA, Salido JP, Urioste A, Poblete G, Sisto AE, Martinez A, Rolón MJ, Ojeda DS, Cahn PE, Turk GJ, Laufer NL.

J Int AIDS Soc. 2019 Sep;22(9):e25375. doi: 10.1002/jia2.25375.

6.

Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection.

Boffito M, Waters L, Cahn P, Paredes R, Koteff J, Van Wyk J, Vincent T, Demarest J, Adkison K, Quercia R.

AIDS Res Hum Retroviruses. 2020 Jan;36(1):13-18. doi: 10.1089/AID.2019.0171. Epub 2019 Oct 21.

PMID:
31507204
7.

Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial.

Tan DHS, Rolon MJ, Figueroa MI, Sued O, Gun A, Kaul R, Raboud JM, Szadkowski L, Hull MW, Walmsley SL, Cahn P; Argentinean GARDEL research network.

PLoS One. 2019 Sep 6;14(9):e0221653. doi: 10.1371/journal.pone.0221653. eCollection 2019.

8.

Onramp to Scholarship: Putting Clinical Faculty Members on the Path to Academic Productivity.

Cahn PS.

J Contin Educ Health Prof. 2019 Summer;39(3):218-222. doi: 10.1097/CEH.0000000000000260.

PMID:
31306281
9.

Once-Daily Doravirine for Initial Treatment of Adults Living With HIV-1: An Integrated Safety Analysis.

Thompson M, Orkin C, Molina JM, Sax P, Cahn P, Squires K, Xu X, Rodgers A, Kumar S, Teppler H, Martin E, Hanna G, Hwang C.

Clin Infect Dis. 2019 May 23. pii: ciz423. doi: 10.1093/cid/ciz423. [Epub ahead of print]

PMID:
31121013
10.

Suicidal Ideation Among Adults Re-engaging in HIV Care in Argentina.

Mandell LN, Rodriguez VJ, De La Rosa A, Abbamonte JM, Sued O, Cecchini D, Cassetti I, Cahn P, Weiss SM, Jones DL; COPA Study Group.

AIDS Behav. 2019 Dec;23(12):3427-3434. doi: 10.1007/s10461-019-02526-4.

PMID:
31049810
11.

Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.

Johnson M, Kumar P, Molina JM, Rizzardini G, Cahn P, Bickel M, Mallolas J, Zhou Y, Morais C, Kumar S, Sklar P, Hanna GJ, Hwang C, Greaves W; DRIVE-SHIFT Study Group.

J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):463-472. doi: 10.1097/QAI.0000000000002056.

PMID:
30985556
12.

Impact of HIV-ART on the restoration of Th17 and Treg cells in blood and female genital mucosa.

Caruso MP, Falivene J, Holgado MP, Zurita DH, Laufer N, Castro C, Nico Á, Maeto C, Salido J, Pérez H, Salomón H, Cahn P, Sued O, Fink V, Turk G, Gherardi MM.

Sci Rep. 2019 Feb 13;9(1):1978. doi: 10.1038/s41598-019-38547-1.

13.

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.

Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K; GEMINI Study Team.

Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9. Erratum in: Lancet. 2018 Nov 28;:.

PMID:
30420123
14.

Effect of valaciclovir on CD4 count decline in untreated HIV: an international randomized controlled trial.

Tan DHS, Raboud JM, Szadkowski L, Grinsztejn B, Madruga JV, Figueroa MI, Cahn P, Barton SE, Clarke A, Fox J, Zubyk W, Walmsley SL; VALIDATE Study Group.

J Antimicrob Chemother. 2019 Feb 1;74(2):480-488. doi: 10.1093/jac/dky433.

15.

Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1.

Jaworski JP, Cahn P.

Lancet HIV. 2018 Dec;5(12):e723-e731. doi: 10.1016/S2352-3018(18)30174-7. Epub 2018 Sep 21. Review.

PMID:
30245003
16.

Expert consensus statement on the science of HIV in the context of criminal law.

Barré-Sinoussi F, Abdool Karim SS, Albert J, Bekker LG, Beyrer C, Cahn P, Calmy A, Grinsztejn B, Grulich A, Kamarulzaman A, Kumarasamy N, Loutfy MR, El Filali KM, Mboup S, Montaner JS, Munderi P, Pokrovsky V, Vandamme AM, Young B, Godfrey-Faussett P.

J Int AIDS Soc. 2018 Jul;21(7):e25161. doi: 10.1002/jia2.25161.

17.

Physician-delivered motivational interviewing to improve adherence and retention in care among challenging HIV-infected patients in Argentina (COPA2): study protocol for a cluster randomized controlled trial.

Sued O, Cassetti I, Cecchini D, Cahn P, de Murillo LB, Weiss SM, Mandell LN, Soni M, Jones DL.

Trials. 2018 Jul 24;19(1):396. doi: 10.1186/s13063-018-2758-5.

18.

Competent in any context: An integrated model of interprofessional education.

Cahn PS, Tuck I, Knab MS, Doherty RF, Portney LG, Johnson AF.

J Interprof Care. 2018 Jul 24:1-4. doi: 10.1080/13561820.2018.1500454. [Epub ahead of print]

PMID:
30040509
19.

Computational comparison of availability in CTL/gag epitopes among patients with acute and chronic HIV-1 infection.

Damilano GD, Sued O, Ruiz MJ, Ghiglione Y, Canitano F, Pando M, Turk G, Cahn P, Salomón H, Dilernia D.

Vaccine. 2018 Jun 27;36(28):4142-4151. doi: 10.1016/j.vaccine.2018.04.086. Epub 2018 May 22.

PMID:
29802001
20.

Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial.

Cahn P, Sax PE, Squires K, Molina JM, Ratanasuwan W, Rassool M, Bloch M, Xu X, Zhou Y, Homony B, Hepler D, Teppler H, Hanna GJ, Nguyen BY, Greaves W; ONCEMRK Study Group.

J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):589-598. doi: 10.1097/QAI.0000000000001723.

21.

Fostemsavir: a new CD4 attachment inhibitor.

Cahn P, Fink V, Patterson P.

Curr Opin HIV AIDS. 2018 Jul;13(4):341-345. doi: 10.1097/COH.0000000000000469. Review.

PMID:
29771694
22.

Survival after cancer diagnosis in a cohort of HIV-positive individuals in Latin America.

Fink VI, Jenkins CA, Castilho JL, Person AK, Shepherd BE, Grinsztejn B, Netto J, Crabtree-Ramirez B, Cortés CP, Padgett D, Jayathilake K, McGowan C, Cahn P; CCASAnet.

Infect Agent Cancer. 2018 May 8;13:16. doi: 10.1186/s13027-018-0188-3. eCollection 2018.

23.

In Reply.

Cahn PS.

Acad Med. 2018 May;93(5):675. doi: 10.1097/ACM.0000000000002153. No abstract available.

PMID:
29688978
24.

Suicidality among nonadherent patients living with HIV in Buenos Aires, Argentina: prevalence and correlates.

Rodriguez VJ, Sued O, Cecchini D, Mandell LN, Bofill LM, Weiss SM, Cassetti I, Cahn P, Jones DL.

AIDS Care. 2018 Nov;30(11):1380-1387. doi: 10.1080/09540121.2018.1458974. Epub 2018 Apr 1.

25.

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.

Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Xu X, Rodgers A, Lupinacci L, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C; DRIVE-FORWARD Study Group.

Lancet HIV. 2018 May;5(5):e211-e220. doi: 10.1016/S2352-3018(18)30021-3. Epub 2018 Mar 25.

PMID:
29592840
26.

Virologic failure and mortality in older ART initiators in a multisite Latin American and Caribbean Cohort.

Carriquiry G, Giganti MJ, Castilho JL, Jayathilake K, Cahn P, Grinsztejn B, Cortes C, Pape JW, Padgett D, Sierra-Madero J, McGowan CC, Shepherd BE, Gotuzzo E.

J Int AIDS Soc. 2018 Mar;21(3):e25088. doi: 10.1002/jia2.25088.

27.

Getting on the same page: an interprofessional common reading program as foundation for patient-centered care.

Doherty RF, Knab M, Cahn PS.

J Interprof Care. 2018 Jul;32(4):444-451. doi: 10.1080/13561820.2018.1433135. Epub 2018 Feb 20.

PMID:
29461137
28.

Preparing Future Health Professionals for Interprofessional Collaborative Practice Part 2: The Student Experience.

Knab M, Inzana RS, Cahn PS, Reidy PA.

Semin Speech Lang. 2017 Nov;38(5):342-349. doi: 10.1055/s-0037-1607069. Epub 2017 Oct 27. Review. No abstract available.

PMID:
29078220
29.

CD4+ T cells and natural killer cells: Biomarkers for hepatic fibrosis in human immunodeficiency virus/hepatitis C virus-coinfected patients.

Laufer N, Ojeda D, Polo ML, Martinez A, Pérez H, Turk G, Cahn P, Zwirner NW, Quarleri J.

World J Hepatol. 2017 Sep 8;9(25):1073-1080. doi: 10.4254/wjh.v9.i25.1073.

30.

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.

Cahn P, Kaplan R, Sax PE, Squires K, Molina JM, Avihingsanon A, Ratanasuwan W, Rojas E, Rassool M, Bloch M, Vandekerckhove L, Ruane P, Yazdanpanah Y, Katlama C, Xu X, Rodgers A, East L, Wenning L, Rawlins S, Homony B, Sklar P, Nguyen BY, Leavitt R, Teppler H; ONCEMRK Study Group.

Lancet HIV. 2017 Nov;4(11):e486-e494. doi: 10.1016/S2352-3018(17)30128-5. Epub 2017 Sep 11.

PMID:
28918877
31.

The HIV care cascade in Buenos Aires, Argentina: results in a tertiary referral hospital.

Cesar C, Blugerman G, Valiente JA, Rebeiro P, Sued O, Fink V, Soto MR, Cillis R, Yamamoto C, Falistocco C, Cahn P, Pérez H.

Rev Panam Salud Publica. 2016 Dec;40(6):448-454.

32.

A decade of HAART in Latin America: Long term outcomes among the first wave of HIV patients to receive combination therapy.

Wolff MJ, Giganti MJ, Cortes CP, Cahn P, Grinsztejn B, Pape JW, Padgett D, Sierra-Madero J, Gotuzzo E, Duda SN, McGowan CC, Shepherd BE; Caribbean, Central and South America Network for HIV Epidemiology.

PLoS One. 2017 Jun 26;12(6):e0179769. doi: 10.1371/journal.pone.0179769. eCollection 2017.

33.

Prevalence of cryptococcal infection among advanced HIV patients in Argentina using lateral flow immunoassay.

Frola C, Guelfand L, Blugerman G, Szyld E, Kaufman S, Cahn P, Sued O, Pérez H.

PLoS One. 2017 Jun 15;12(6):e0178721. doi: 10.1371/journal.pone.0178721. eCollection 2017.

34.

Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study.

Cahn P, Rolón MJ, Figueroa MI, Gun A, Patterson P, Sued O.

J Int AIDS Soc. 2017 May 9;20(1):21678. doi: 10.7448/IAS.20.01.21678.

35.

Candidates for inclusion in a universal antiretroviral regimen: dolutegravir.

Cahn P.

Curr Opin HIV AIDS. 2017 Jul;12(4):318-323. doi: 10.1097/COH.0000000000000388. Review.

PMID:
28520610
36.
37.

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial.

Thompson M, Lalezari JP, Kaplan R, Pinedo Y, Pena OAS, Cahn P, Stock DA, Joshi SR, Hanna GJ, Lataillade M; AI438011 study team.

Antivir Ther. 2017;22(3):215-223. doi: 10.3851/IMP3112. Epub 2016 Dec 6.

PMID:
27922453
38.

Seven Dirty Words: Hot-Button Language That Undermines Interprofessional Education and Practice.

Cahn PS.

Acad Med. 2017 Aug;92(8):1086-1090. doi: 10.1097/ACM.0000000000001469.

PMID:
27805953
39.

Implementation and uptake of the Conexiones y Opciones en la Argentina intervention: feasibility and acceptability.

Jones DL, Lucas M, Arístegui I, Bordato A, Fernandez-Cabanillas G, Zalazar V, Sued O, Cecchini D, Cassetti I, Cahn P, Bofill L, Weiss SM.

AIDS Care. 2016 Oct;28(10):1287-95. doi: 10.1080/09540121.2016.1178697. Epub 2016 Apr 27.

40.

Clinical challenges in HIV/AIDS: Hints for advancing prevention and patient management strategies.

Sued O, Figueroa MI, Cahn P.

Adv Drug Deliv Rev. 2016 Aug 1;103:5-19. doi: 10.1016/j.addr.2016.04.016. Epub 2016 Apr 23. Review.

PMID:
27117711
41.

Assessing the HIV Care Continuum in Latin America: progress in clinical retention, cART use and viral suppression.

Rebeiro PF, Cesar C, Shepherd BE, De Boni RB, Cortés CP, Rodriguez F, Belaunzarán-Zamudio P, Pape JW, Padgett D, Hoces D, McGowan CC, Cahn P.

J Int AIDS Soc. 2016 Apr 8;19(1):20636. doi: 10.7448/IAS.19.1.20636. eCollection 2016.

42.

A picture is worth a thousand words: maps of HIV indicators to inform research, programs, and policy from NA-ACCORD and CCASAnet clinical cohorts.

Althoff KN, Rebeiro PF, Hanna DB, Padgett D, Horberg MA, Grinsztejn B, Abraham AG, Hogg R, Gill MJ, Wolff MJ, Mayor A, Rachlis A, Williams C, Sterling TR, Kitahata MM, Buchacz K, Thorne JE, Cesar C, Cordero FM, Rourke SB, Sierra-Madero J, Pape JW, Cahn P, McGowan C; North American Aids Cohort Collaboration on Research and Design (NA-ACCORD) and Caribbean, Central and South America Network for Hiv Epidemiology (CCASAnet).

J Int AIDS Soc. 2016 Apr 4;19(1):20707. doi: 10.7448/IAS.19.1.20707. eCollection 2016.

43.

A design thinking approach to evaluating interprofessional education.

Cahn PS, Bzowyckyj A, Collins L, Dow A, Goodell K, Johnson AF, Klocko D, Knab M, Parker K, Reeves S, Zierler BK.

J Interprof Care. 2016 May;30(3):378-80. doi: 10.3109/13561820.2015.1122582. Epub 2016 Mar 30.

PMID:
27030030
44.

Health outcomes among HIV-positive Latinos initiating antiretroviral therapy in North America versus Central and South America.

Cesar C, Koethe JR, Giganti MJ, Rebeiro P, Althoff KN, Napravnik S, Mayor A, Grinsztejn B, Wolff M, Padgett D, Sierra-Madero J, Gotuzzo E, Sterling TR, Willig J, Levison J, Kitahata M, Rodriguez-Barradas MC, Moore RD, McGowan C, Shepherd BE, Cahn P; Caribbean, Central and South America Network for HIV epidemiology (CCASAnet) and North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).

J Int AIDS Soc. 2016 Mar 18;19(1):20684. doi: 10.7448/IAS.19.1.20684. eCollection 2016.

45.

Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients.

Baril JG, Angel JB, Gill MJ, Gathe J, Cahn P, van Wyk J, Walmsley S.

PLoS One. 2016 Feb 5;11(2):e0148231. doi: 10.1371/journal.pone.0148231. eCollection 2016. Review.

46.

Incidence of virological failure and major regimen change of initial combination antiretroviral therapy in the Latin America and the Caribbean: an observational cohort study.

Cesar C, Jenkins CA, Shepherd BE, Padgett D, Mejía F, Ribeiro SR, Cortes CP, Pape JW, Madero JS, Fink V, Sued O, McGowan C, Cahn P; Caribbean, Central and South America Network for HIV Epidemiology (CCASAnet) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Program.

Lancet HIV. 2015 Nov;2(11):e492-500. doi: 10.1016/S2352-3018(15)00183-6. Epub 2015 Oct 22.

47.

High diversity of human polyomaviruses in environmental and clinical samples in Argentina: Detection of JC, BK, Merkel-cell, Malawi, and human 6 and 7 polyomaviruses.

Torres C, Barrios ME, Cammarata RV, Cisterna DM, Estrada T, Martini Novas S, Cahn P, Blanco Fernández MD, Mbayed VA.

Sci Total Environ. 2016 Jan 15;542(Pt A):192-202. doi: 10.1016/j.scitotenv.2015.10.047. Epub 2015 Oct 29.

PMID:
26519580
48.

Env-Specific IgA from Viremic HIV-Infected Subjects Compromises Antibody-Dependent Cellular Cytotoxicity.

Ruiz MJ, Ghiglione Y, Falivene J, Laufer N, Holgado MP, Socías ME, Cahn P, Sued O, Giavedoni L, Salomón H, Gherardi MM, Rodríguez AM, Turk G.

J Virol. 2016 Jan 15;90(2):670-81. doi: 10.1128/JVI.02363-15. Print 2016 Jan 15.

49.

Monitoring of HIV treatment in seven countries in the WHO Region of the Americas.

Belaunzarán-Zamudio PF, Caro-Vega YN, Shepherd BE, Crabtree-Ramírez BE, Luz PM, Grinsztejn B, Cesar C, Cahn P, Cortés C, Wolff M, Pape JW, Padgett D, Gotuzzo E, McGowan C, Sierra-Madero JG; CCASAnet.

Bull World Health Organ. 2015 Aug 1;93(8):529-39. doi: 10.2471/BLT.14.147447. Epub 2015 May 27.

50.

The Vancouver Consensus: antiretroviral medicines, medical evidence, and political will.

Beyrer C, Birx DL, Bekker LG, Barré-Sinoussi F, Cahn P, Dybul MR, Eholié SP, Kavanagh MM, Katabira ET, Lundgren JD, Mworeko L, Pala M, Puttanakit T, Ryan O, Sidibé M, Montaner JS; Vancouver Consensus Signatories.

Lancet. 2015 Aug 8;386(9993):505-7. doi: 10.1016/S0140-6736(15)61458-1. No abstract available.

PMID:
26293427

Supplemental Content

Support Center